Ad
related to: MERCK & CO., INCscbn.org has been visited by 10K+ users in the past month
Search results
Merck to Acquire EyeBio
Morningstar· 2 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the ...
Merck On Track for Largest Percent Decrease Since October 2023 — Data Talk
Morningstar· 2 days agoMerck & Co., Inc. (MRK) is currently at $126.30, down $3.19 or 2.46% --Would be lowest close since April 19, 2024, when it closed at ...
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Benzinga· 2 days agoEditor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead...
Unveiling Merck (MRK)'s Value: Is It Really Priced Right? A Comp
Guru Focus· 2 days agoMerck & Co Inc (MRK, Financial) recently experienced a daily loss of 2.46%, contributing to a three-month decline of 0.74%. With an Earnings ...
Merck to buy EyeBio in a deal that could valued at up to $3 billion
Market Watch· 1 day agoannounced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via AOL· 6 days agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...
Merck Announces Third-Quarter 2024 Dividend
Morningstar· 2 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common ...
Europe Bond Sales Exceed €1 Trillion in Record Time
Bloomberg via Yahoo Finance· 1 day ago(Bloomberg) -- European bond issuance this year has topped the €1 trillion ($1.1 trillion) mark more than a week before the previous record.Most Read...
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
Benzinga· 3 days agoHELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American
Ken Griffin Is Snapping Up These Dividend Stocks: Hess And 2 More
Benzinga via Yahoo Finance· 3 days agoKen Griffin, founder of Citadel in 1990, is widely regarded as a leading figure among contemporary...
